Xenon Pharmaceuticals (FRA:XP0) EPS (Basic) : €-2.51 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals EPS (Basic)?

Xenon Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was €-0.57. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.51.

Xenon Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2024 was €-0.57. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.51.

Xenon Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was €-0.57. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -2.53.

During the past 3 years, the average EPS without NRI Growth Rate was -50.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Xenon Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 22.90% per year. The lowest was -50.20% per year. And the median was -8.90% per year.

Xenon Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Xenon Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals EPS (Basic) Chart

Xenon Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.39

-0.67

-1.57

-1.95

-2.50

Xenon Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-0.59	-0.67	-0.68	-0.59	-0.57

Xenon Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Xenon Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-167.254	-	0)	/	66.889
	=	-2.50

Xenon Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-44.097	-	0)	/	77.595
	=	-0.57

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.51

Xenon Pharmaceuticals (FRA:XP0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Xenon Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenon Pharmaceuticals (FRA:XP0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (FRA:XP0) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

XENE:USA

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Xenon Pharmaceuticals (FRA:XP0) Headlines

No Headlines